title: FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.
abstract: High-throughput genomic technologies have identified biomarkers and potential therapeutic targets for ovarian cancer. Comprehensive functional validation studies of the biological and clinical implications of these biomarkers are needed to advance them toward clinical use. Amplification of chromosomal region 5q31-5q35.3 has been used to predict poor prognosis in patients with advanced stage, high-grade serous ovarian cancer. In this study, we further dissected this large amplicon and identified the overexpression of FGF18 as an independent predictive marker for poor clinical outcome in this patient population. Using cell culture and xenograft models, we show that FGF18 signaling promoted tumor progression by modulating the ovarian tumor aggressiveness and microenvironment. FGF18 controlled migration, invasion, and tumorigenicity of ovarian cancer cells through NF-κB activation, which increased the production of oncogenic cytokines and chemokines. This resulted in a tumor microenvironment characterized by enhanced angiogenesis and augmented tumor-associated macrophage infiltration and M2 polarization. Tumors from ovarian cancer patients had increased FGF18 expression levels with microvessel density and M2 macrophage infiltration, confirming our in vitro results. These findings demonstrate that FGF18 is important for a subset of ovarian cancers and may serve as a therapeutic target.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.forename: Samuel C
authors.initials: SC
authors.lastname: Mok
authors.forename: Esther
authors.initials: E
authors.lastname: Oliva
authors.forename: Sung-hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Gayatry
authors.initials: G
authors.lastname: Mohapatra
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Birrer
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D045744:Cell Line, Tumor; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D005260:Female; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D051379:Mice; D016513:Mice, SCID; D055806:Microvessels / Q000473:pathology; D009368:Neoplasm Transplantation; D009375:Neoplasms, Glandular and Epithelial / Q000098:blood supply / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011379:Prognosis; D016016:Proportional Hazards Models; D015398:Signal Transduction; D059467:Transcriptome; D047368:Tumor Burden; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D016207:Cytokines; D019408:Platelet Endothelial Cell Adhesion Molecule-1; C113569:fibroblast growth factor 18; D005346:Fibroblast Growth Factors
references.citation: J Biol Chem. 2006 Jun 9;281(23):15694-700
references.pmid: 16597617
references.citation: Annu Rev Pathol. 2010;5:99-118
references.pmid: 20078217
references.citation: Breast Cancer Res Treat. 1995;36(2):169-80
references.pmid: 8534865
references.citation: Cell. 2010 Apr 2;141(1):39-51
references.pmid: 20371344
references.citation: PLoS One. 2009 Aug 10;4(8):e6562
references.pmid: 19668347
references.citation: PLoS One. 2012;7(2):e30996
references.pmid: 22355333
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2281-7
references.pmid: 17538174
references.citation: Biochemistry. 2003 Apr 22;42(15):4569-77
references.pmid: 12693954
references.citation: Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9
references.pmid: 17218844
references.citation: PLoS One. 2011;6(7):e21121
references.pmid: 21754983
references.citation: Cancer Cell. 2009 Dec 8;16(6):521-32
references.pmid: 19962670
references.citation: Clin Cancer Res. 2013 Feb 15;19(4):809-20
references.pmid: 23344261
references.citation: Nature. 2011 Jun 29;474(7353):609-15
references.pmid: 21720365
references.citation: Physiol Genomics. 2011 Nov 7;43(21):1226-40
references.pmid: 21878612
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Gastric Cancer. 2010 Nov;13(4):212-21
references.pmid: 21128056
references.citation: Neoplasia. 2011 May;13(5):393-405
references.pmid: 21532880
references.citation: Gynecol Oncol. 2011 Apr;121(1):230-8
references.pmid: 21215996
references.citation: Breast Cancer Res. 2012 Jun 25;14(3):R97
references.pmid: 22731827
references.citation: Cancer Cell. 2007 Dec;12(6):559-71
references.pmid: 18068632
references.citation: Sci Transl Med. 2013 Mar 27;5(178):178ra39
references.pmid: 23536011
references.citation: Endocr Relat Cancer. 2007 Dec;14(4):1039-52
references.pmid: 18045955
references.citation: Biochim Biophys Acta. 2011 Dec;1816(2):119-31
references.pmid: 21658434
references.citation: Cancer Causes Control. 2011 May;22(5):785-801
references.pmid: 21359843
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4067-78
references.pmid: 18593983
references.citation: Cancer Res. 2011 Jan 15;71(2):349-59
references.pmid: 21224353
references.citation: Cancer Cell. 2007 Apr;11(4):321-33
references.pmid: 17418409
references.citation: Genes Dev. 2004 Sep 15;18(18):2195-224
references.pmid: 15371334
references.citation: Histol Histopathol. 2007 Jan;22(1):97-105
references.pmid: 17128416
references.citation: J Biol Chem. 2004 Sep 10;279(37):38209-19
references.pmid: 15252029
references.citation: Trends Mol Med. 2011 May;17(5):283-92
references.pmid: 21367659
references.citation: Nat Rev Immunol. 2002 Sep;2(9):664-74
references.pmid: 12209135
references.citation: Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49
references.pmid: 15863030
references.citation: Biochem Biophys Res Commun. 2006 Jul 21;346(1):224-33
references.pmid: 16756958
references.citation: Nat Rev Cancer. 2010 Feb;10(2):116-29
references.pmid: 20094046
references.citation: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7
references.pmid: 17060621
references.citation: J Biol Chem. 1999 Mar 26;274(13):9045-52
references.pmid: 10085153
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4700-10
references.pmid: 15505275
references.citation: Curr Drug Targets. 2010 Sep;11(9):1133-46
references.pmid: 20545607
references.citation: Nat Rev Cancer. 2008 Aug;8(8):618-31
references.pmid: 18633355
references.citation: Dev Biol. 2007 Feb 1;302(1):80-91
references.pmid: 17014841
references.citation: Minerva Med. 2009 Oct;100(5):357-70
references.pmid: 19910889
references.citation: Cancer Res. 2007 Jun 15;67(12):5708-16
references.pmid: 17575137
references.citation: Nucleic Acids Res. 1998 Mar 15;26(6):1433-9
references.pmid: 9490789